AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...
The integration of Polarean’s Xenon MRI platform into SimonMed’s facilities represents a new business opportunity to expand the availability of functional lung imaging. This collaboration underscores ...